Using Rubidium PET to Assess Kidney Blood Flow
Assessment of Renal Microcirculation With Rubidium Positron Emission Tomography: A Proof-of-Concept Study
Montreal Heart Institute · NCT06332456
This study is testing if a special imaging technique using Rubidium can help us understand kidney blood flow better in people with chronic kidney disease compared to healthy individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Montreal Heart Institute (other) |
| Locations | 1 site (Montréal, Quebec) |
| Trial ID | NCT06332456 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate renal microcirculation by using Rubidium-82 positron emission tomography (PET) to measure renal blood flow (RBF) and renal vascular resistance (RVR) in both healthy individuals and patients with chronic kidney disease (CKD). The researchers will compare RBF in CKD patients with coronary artery disease risk factors to that of healthy controls, and assess the correlation between RVR measured by PET and traditional echographic methods. Additionally, the study will investigate the reproducibility of RBF measurements using PET imaging.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 80 with chronic kidney disease and cardiovascular risk factors, as well as healthy controls without a history of renal disease.
Not a fit: Patients with severe aortic stenosis, documented renal artery stenosis, or those requiring dialysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and evaluation of renal diseases, leading to improved diagnostic and treatment strategies for patients with kidney conditions.
How similar studies have performed: While the use of PET imaging in renal assessment is emerging, this specific application with Rubidium-82 is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Control Group 1. Age ≥ 18 years and \< 80 years 2. Signed informed consent 3. No medical history of renal disease CKD Group 1. Age ≥ 18 years and \< 80 years 2. Signed informed consent 3. GFR between 30 and 45 mL/min/1.73m2 measured within the last 3 months 4. At least two cardiovascular disease risk factors such as hypertension, smoking, diabetes, obesity, and dyslipidemia Exclusion Criteria: Control Group 1. Hypertension 2. Diabetes 3. Dyslipidemia 4. Active smoking within the last 12 month 5. Left ventricular ejection fraction \<45% 6. BMI \>45 kg/m2 7. Severe aortic stenosis CKD Group 1. Left ventricular ejection fraction \<45% 2. BMI \>45 kg/m2 3. Severe aortic stenosis 4. Changes in medical therapy within the last 4 weeks 5. Documented renal artery stenosis 6. Known structural cause of CKD including polycystic kidney disease, obstruction, or other post-renal causes 7. Pregnancy or breastfeeding 8. Renal failure requiring dialysis within the last 90 days
Where this trial is running
Montréal, Quebec
- Montreal Heart Institute — Montréal, Quebec, Canada (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Renal Microcirculation With Rubidium Positron Emission Tomography